Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ: Androgen receptor expression in estrogen receptor-bad cancer of the breast Bieche We, Parfait B, Tozlu S, Lidereau R, Vidaud Yards: Quantitation out of androgen receptor gene term into the sporadic breast tumors of the real-big date RT-PCR: evidence that MYC try an enthusiastic AR-regulated gene.
Bieche We, Parfait B, Tozlu S, Lidereau R, Vidaud Yards: Quantitation out of androgen receptor gene term into the sporadic breast tumors of the real-big date RT-PCR: evidence that MYC try an enthusiastic AR-regulated gene. Carcinogenesis. 2001, twenty two (9): 1521-1526. /carcin/22.9.1521.
Bratthauer GL, Lininger RA, Man YG, Tavassoli FA: Androgen and you can estrogen receptor mRNA standing in apocrine carcinomas. Diagn Mol Pathol. 2002, 11 (2): 113-118. 9606-200206000-00008.
Gatalica Z: Immunohistochemical research from apocrine nipple sores. Uniform more than-term of androgen receptor with the loss of the hormone estrogen and you will progesterone receptors within the apocrine metaplasia and you can apocrine carcinoma for the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.
Was J Clin Pathol
Soreide JA, Lea OA, Varhaug JE, Skarstein An effective, Kvinnsland S: Androgen receptors into the operable cancer of the breast: regards to most other steroid hormones receptors, correlations to prognostic items and you may predictive value having effect of additive tamoxifen therapy. Eur J Surg Oncol. 1992, 18 (2): 112-118.
Bayer-Garner IB, Smoller B: Androgen receptors: a beneficial marker to boost susceptibility getting determining cancer of the breast inside surface metastasis from unfamiliar pri, 13 (2): 119-122. /modpathol.3880021.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and you will systematic effects. J Clin Oncol. 2000, 18 (5): 1135-1149.
Pang ST, Flores-Morales A great, Skoog L, Chuan YC, Nordstedt Grams, Pousette A beneficial: Controls away from matrix metalloproteinase thirteen phrase by androgen into the prostate cancers. Oncol Associate. 2004, 11 (6): 1187-1192.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.
Schippinger W, Regitnig P, Dandachi Letter, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Comparison of prognostic dependence on androgen receptor term inside metastatic cancer of the breast. Virchows Arch. 2006, 449 (1): 24-31. /s00428-006-0213-6.
Parker RL, Huntsman DG, Lesack DW, Cupples JB, Offer DR, Akbari M, Gilks CB: Assessment of interlaboratory variation on immunohistochemical devotion out-of the hormone estrogen receptor standing playing with a breast cancer cells microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Examination of matrix metalloproteinases as well as their inhibitors from inside the cancer of the breast. Br J Cancer tumors. 2007, 96 (6): 903-911. /sj.bjc.6603666.
Narita D, Raica Meters, Suciu C, Cimpean Good, Anghel Good: Immunohistochemical term off androgen receptor and you will prostate-particular antigen in cancer of the breast. Folia Histochem Cytobiol. 2006, forty two (3): 165-172.
Egeblad Yards, Werb Z: The latest features on matrix metalloproteinases inside the cancer tumors advancement. Nat Rev Cancer tumors. 2002, dos (3): 161-174. /nrc745.
Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–into chief phase off cancer?. Cancer Cell. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.
Manes S, Llorente Yards, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Elizabeth, Martinez Air conditioning: The latest matrix metalloproteinase-9 handles the newest insulin-such as for example development grounds-triggered autocrine impulse into the DU-145 carcinoma structure. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel Yards: Launch of an attack supporter E-cadherin fragment by matrilysin and you can stromelysin-step 1. J Telephone Sci. 2001, 114 (Pt step 1): 111-118.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] term selects to have tissues with reduced sensitivity in order to apoptosis. Neoplasia. 2001, 3 (6): 459-468. /sj.neo.7900190.
CO;2-H
Stetler-Stevenson WG: Matrix metalloproteinases into the angiogenesis: a moving target to possess healing input. J Clin Invest. 1999, 103 (9): 1237-1241. /JCI6870.
Cornelius La, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD: Matrix metalloproteinases generate angiostatin: consequences https://datingranking.net/tr/milfaholic-inceleme/ on the neovascularization. J Immunol. 1998, 161 (12): 6845-6852.
Jiang Y, Goldberg ID, Shi YE: State-of-the-art opportunities from cells inhibitors out of metalloproteinases when you look at the cancer tumors. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.
Leave a Comment
Your email address will not be published. Required fields are marked with *